| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/27/2005 | CN1198818C Compound with growth hormone releasing properties |
| 04/27/2005 | CN1198814C Salt |
| 04/27/2005 | CN1198799C Crystalline form of (S)-2-ethoxy-3-[4-(2-{4-methane sulfonyloxy phenyl}ethoxy)phenyl] propanoic acid |
| 04/27/2005 | CN1198653C Preparations for preventing bile acid diarrhea |
| 04/27/2005 | CN1198646C Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens |
| 04/27/2005 | CN1198640C Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/27/2005 | CN1198637C Health cosmetic composition |
| 04/27/2005 | CN1198629C Biology calcium health foods made from sierra fish bone and its preparation method |
| 04/27/2005 | CN1198618C Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts |
| 04/27/2005 | CN1198608C Therapeutic and dietary compsns. containing essential fatty acids and bioactive disulphides |
| 04/27/2005 | CN1198597C Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor |
| 04/27/2005 | CN1198595C Process for preparation of spraying granule of ovoflaving |
| 04/27/2005 | CN1198589C Method for controlling liposome size |
| 04/27/2005 | CN1198588C Multilayer emulsion for stabilization of effective component on dermatology and externally used preparation using it |
| 04/26/2005 | US6884907 Containing carboxylic acid groups; diagnosis; prophylaxis |
| 04/26/2005 | US6884804 Inhibitors of Src and other protein kinases |
| 04/26/2005 | US6884801 Nitrogen compounds such as N-(4,5-dihydro-1H-imidazol-2-yl-methyl)-2-(methylsulfonyl)aniline, used for prophylaxis of incontinence |
| 04/26/2005 | US6884800 Nitrogen compounds such as 10-Chloro-3-imidazol-1-yl-2,3-dihydro-1H-pyrido(3,2,1-kl)phenothiazine, used for prophylaxis of respiratory system and skin disorders, autoimune diseases, tumors or atherosclerosis and AIDS |
| 04/26/2005 | US6884795 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol |
| 04/26/2005 | US6884785 Compositions and methods for the treatment or prevention of autoimmune diabetes |
| 04/26/2005 | US6884575 Diagnosis and treatment of insulin resistance in diabetics; obtain humans, administer modulator of insulin resistance, monitor human response to insulin |
| 04/26/2005 | US6884574 Methods of identifying agents which inhibit GPR-9-6 |
| 04/26/2005 | US6884413 Immunosuppressants for organ transplantions by inducing apoptosis/anergy in T cells; genetic engineering; antigen presenting cells |
| 04/26/2005 | CA2123052C Monomeric bile acid derivatives, processes for their preparation and the use of these compounds as medicaments |
| 04/21/2005 | WO2005035546A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | WO2005035536A1 Novel xanthone derivative, process for producing the same and pharmaceutical composition containing the same |
| 04/21/2005 | WO2005035516A1 Novel fused heterocyclic compound and use thereof |
| 04/21/2005 | WO2005035498A1 Use of nitrogenous bicyclic compound as feeding control agent |
| 04/21/2005 | WO2005034986A1 Remedy for kidney diseases |
| 04/21/2005 | WO2005034973A1 Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii) |
| 04/21/2005 | WO2005034962A1 Methods and means for modulating lipid metabolism |
| 04/21/2005 | WO2005034953A1 Angiogenesis inhibitor |
| 04/21/2005 | WO2005034947A1 Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 04/21/2005 | WO2005034650A1 Weight-loss supplement |
| 04/21/2005 | WO2005018664B1 Method and cosmetic product containing beta-endorphin, which are intended to limit fatty tissue growth |
| 04/21/2005 | WO2005000339A8 Melanocortin receptor 4(mc4) agonists and their uses |
| 04/21/2005 | WO2004111019A3 Protective groups cleavable by serumal albumins |
| 04/21/2005 | WO2004022076A8 Branched alpha-glucans for weight management |
| 04/21/2005 | WO2002098348A3 Glp-1 formulations with protracted time action |
| 04/21/2005 | US20050085644 Antidiabetic agents; insulin resistance |
| 04/21/2005 | US20050085541 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| 04/21/2005 | US20050085535 Lipase inhibiting polymers |
| 04/21/2005 | US20050085532 Prevention, therapy of central nervous system disorders ; antidepressants; anxiolytic agents; eating and sleep disorders; Alzheimer's disease; strokes; schizophrenia; incontinence; gastrointestinal disorders; cardiovascular disorders |
| 04/21/2005 | US20050085531 Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 04/21/2005 | US20050085514 Psychological disorders; schizophrenia; anxiolytic agents; antidepressants; bipolar diseases; circadian rhythm disorders; analgesics; Parkinson's disease; Huntington's disease |
| 04/21/2005 | US20050085509 KInase inhibitors; antiarthritic agents; autoimmune diseases; sepsis; cachexia; Alzheimer's disease; antihistamines; thrombosis; glomerulonephritis; inflammatory bowel disorders; crohn's disese; multiple sclerosis; antitumor agents; skin disorders |
| 04/21/2005 | US20050085497 Anticholesterol agents; reducing blood serum lipids; anticancer agents; antiarthritic agents; antiinflammatory agents; antitumor agents; immunosuppressants; obesity; hypotensive agents |
| 04/21/2005 | US20050085489 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 04/21/2005 | US20050085488 nitrogen compounds used as preferential inhibitors of cyclic peptide, for prophylaxis of metabolic disorders |
| 04/21/2005 | US20050085476 Polymerase inhibitors; antiischemic agents; brain disorders; cardiovascular disorders; antiinflammatory agents; antiarthritic agents; neurodegenerative agents; Alzheimer's disease; muscular disorders; antidiabetic agents; kidney disorders; viricides; anticancer agents; immunosuppressants |
| 04/21/2005 | US20050085461 Benzenesulfonamide derivatives |
| 04/21/2005 | US20050085460 useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease |
| 04/21/2005 | US20050085457 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 04/21/2005 | US20050085415 Nanoparticles injected directly into eye; integrin receptor antagonist; angiogenesis inhibitor, polypeptide |
| 04/21/2005 | US20050085408 Drugs ameliorating hypo-hdl cholesterolemia |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084840 Method for screening drug for improving insulin resistance |
| 04/21/2005 | US20050084548 Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
| 04/21/2005 | US20050084518 For producing beautiful skin and improving constipation, reducing hair loss |
| 04/21/2005 | US20050084489 Synergistic administration of Vitaxin, a FAB fragment, or a competitive binding antibody for binding integrin alpha V beta 3 with the enzyme inhibitor; antiinflammatory, anticarcinogenic agents; autoimmune and metabolic bone disorders |
| 04/21/2005 | US20050084486 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 04/21/2005 | US20050084476 Orally administering phosphate ion absorbent comprising as an active ingredient a weakly basic anion exchange resin, wherein resin is a copolymer containing as monomer components divinylbenzene and acrylamide or divinylbenzene and acrylate, wherein the copolymer further contains a tertiary amino group |
| 04/21/2005 | CA2578473A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | CA2559836A1 Thermogenic and fiber containing weight-loss supplement |
| 04/21/2005 | CA2541815A1 Methods and means for modulating lipid metabolism |
| 04/21/2005 | CA2541607A1 Therapeutic agents for renal diseases |
| 04/20/2005 | EP1524270A1 Sulfur-containing proanthocyanidin oligomer composition and process for producing the same |
| 04/20/2005 | EP1523983A1 Pharmaceutical composition comprising fenofibrate and process for its preparation |
| 04/20/2005 | EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 04/20/2005 | EP1523571A2 Sgk and nedd used as diagnostic and therapeutic targets |
| 04/20/2005 | EP1523556A1 Methods of treating conditions associated with an edg-1 receptor |
| 04/20/2005 | EP1523541A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 04/20/2005 | EP1523488A1 Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof |
| 04/20/2005 | EP1523486A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 04/20/2005 | EP1523481A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 04/20/2005 | EP1523480A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 04/20/2005 | EP1523475A1 Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| 04/20/2005 | EP1523473A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 04/20/2005 | EP1523471A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 04/20/2005 | EP1523470A1 Novel compounds as histone deacetylase inhibitors |
| 04/20/2005 | EP1523372A2 Ghrelin-carrier conjugates |
| 04/20/2005 | EP1523325A2 Methods and compositions for treating polycystic ovary syndrome |
| 04/20/2005 | EP1523321A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 04/20/2005 | EP1523316A2 Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 04/20/2005 | EP1523314A2 Pyrazolopyrimidines as protein kinase inhibitors |
| 04/20/2005 | EP1392316B1 Benzo[d]azepine derivatives as 5-ht6 receptor antagonists. |
| 04/20/2005 | EP1373249B1 Imidazolidine derivatives, their preparation, and their use as antiinflamatory agent |
| 04/20/2005 | EP1349843B1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 04/20/2005 | EP1314434A4 Agent for regulating lipidic metabolism and method for producing said agent |
| 04/20/2005 | EP1307425B1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 04/20/2005 | EP1307263B1 New use of lipase inhibitors |
| 04/20/2005 | EP1252158B1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 04/20/2005 | EP1226110B1 Bicyclic amino acids as pharmaceutical agents |
| 04/20/2005 | EP1196417B1 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 04/20/2005 | EP1144395B1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1143977B1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1129077B1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 04/20/2005 | EP1001685B1 Nutritional compositions containing methionine |
| 04/20/2005 | EP0949919B1 A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |